Crispr Therapeutics AG (CRSP) Expected to Announce Quarterly Sales of $4.45 Million

Equities analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will announce $4.45 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Crispr Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $11.30 million. Crispr Therapeutics posted sales of $32.33 million during the same quarter last year, which would indicate a negative year over year growth rate of 86.2%. The firm is scheduled to report its next quarterly earnings report on Thursday, March 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next financial year, analysts anticipate that the company will post sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative return on equity of 47.32% and a negative net margin of 331.84%. The company had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. The company’s revenue for the quarter was down 76.6% on a year-over-year basis.

Several brokerages have weighed in on CRSP. Zacks Investment Research upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 12th. Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Monday, September 17th. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. Raymond James began coverage on Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $62.47.

A number of institutional investors and hedge funds have recently modified their holdings of the business. ARK Investment Management LLC grew its stake in shares of Crispr Therapeutics by 211.2% during the 3rd quarter. ARK Investment Management LLC now owns 1,453,590 shares of the company’s stock valued at $64,467,000 after buying an additional 986,450 shares during the period. BlackRock Inc. grew its stake in shares of Crispr Therapeutics by 19.6% during the 3rd quarter. BlackRock Inc. now owns 709,643 shares of the company’s stock valued at $31,471,000 after buying an additional 116,116 shares during the period. Federated Investors Inc. PA purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at $37,101,000. Jennison Associates LLC purchased a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at $23,988,000. Finally, Global Thematic Partners LLC grew its stake in shares of Crispr Therapeutics by 87.7% during the 3rd quarter. Global Thematic Partners LLC now owns 497,276 shares of the company’s stock valued at $22,054,000 after buying an additional 232,362 shares during the period. Institutional investors own 39.49% of the company’s stock.

Shares of CRSP opened at $36.37 on Friday. Crispr Therapeutics has a fifty-two week low of $16.70 and a fifty-two week high of $73.90.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Further Reading: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply